Analytical control of imatinib in bioanalytical samples using graphene quantum dots sensing.
María A García-TrejoGregorio CastañedaAngel RíosPublished in: Analytical and bioanalytical chemistry (2024)
An analytical method for the determination of imatinib (IMA, the primary treatment for chronic myeloid leukemia), based on the fluorescence properties of graphene quantum dots (GQDs), is reported in this work. The method is addressed to the analytical control of IMA in biological and pharmaceutical samples, due to the present interest in the control of the doses of this anticancer drug, as well as the therapeutic monitoring. The whole method involves the use of a solid-phase extraction (SPE) procedure, followed by an evaporation step, for the treatment of biological samples. For that, tC18 sorbent cartridges were used. After the sample treatment, the solution containing the analyte was mixed with an aqueous solution of GQDs at pH 7.2, and the fluorescent quenching of GQDs was measured. IMA was determined in the 10-250 µg L -1 range, with a limit of detection of 21 µg L -1 and a precision of 1.5% as relative standard deviation, measured in terms of reproducibility. The recovery for biological samples was in the 84-113% range.
Keyphrases
- solid phase extraction
- quantum dots
- chronic myeloid leukemia
- liquid chromatography
- molecularly imprinted
- high performance liquid chromatography
- liquid chromatography tandem mass spectrometry
- emergency department
- energy transfer
- aqueous solution
- tandem mass spectrometry
- gas chromatography mass spectrometry
- mass spectrometry
- sensitive detection
- simultaneous determination
- room temperature
- gas chromatography
- combination therapy
- label free
- replacement therapy
- high resolution mass spectrometry
- ionic liquid
- adverse drug